Nervous Disorder TRIZ Cases

Modifying the chemical structure of existing compounds improves pharmacokinetic properties and safety while maintaining therapeutic efficacy.

Gal-1 variants with histidine and cysteine mutations resist acidic and oxidative deactivation in inflammatory microenvironments.

Switching from agonists to antagonists reduces adverse effects while maintaining high tumor uptake of radiolabeled peptides.

Dynamic dose escalation reduces adverse effects in renal impairment while maintaining therapeutic efficacy.

Specific organic solvents and temperature control drive phase transitions that yield high-purity crystals, overcoming inefficient fermentation scalability.

Combining VZV gE antigen with TH1 adjuvant overcomes insufficient immunity in older adults, reducing shingles severity.

A propofol emulsion maintains low free propofol concentrations in the aqueous phase using specific oil and emulsifier ratios.

A thermostable ISG65 mutant binds complement components to reduce hemolysis.

Transplanted MGE precursor cells restore neuronal circuitry balance by integrating with endogenous neurons, reducing tremors and seizure activity.

A phytotherapeutic composition combining grape, ginger, and prickly ash extracts with phospholipid complexes to deliver analgesic effects.

Nicotine reduces autoreactive T cell proliferation and alters cytokine profiles to treat multiple sclerosis.

Transferrin binds deferoxamine to extend its plasma half-life and reduce toxicity while activating the HIF pathway for effective neuroprotection.

Co-crystal of tramadol hydrochloride and celecoxib with solubility enhancer polymer improves bioavailability for pain management.

Human interferon-beta mutein gains additional sugar chains via amino acid substitution and C-terminal extension to enhance antiviral activity.

A liquid-filled capsule formulation uses a surfactant mixture to solubilize drotaverine hydrochloride for stable oral delivery.

Dual RING domain fusion proteins overcome low potency in monomeric targets by forming catalytic topologies that reduce required concentrations.

Exogenous microRNAs direct mesenchymal stem cells to differentiate into neural stem cells and motor neurons.

Combining glycolic acid with L-alanine enhances neuronal plasticity and mitochondrial function.

Intrathecal recombinant arylsulfatase A bypasses the blood-brain barrier to reduce sulfatide levels in cerebrospinal fluid.

Inhibiting PTEN lipid phosphatase activity restores intrinsic axon growth capability suppressed by aging and injury.

Orange peel ferment reduces adipocyte fat content through targeted triglyceride lysis.

Angiopep-2 conjugates transport imaging agents across the blood-brain barrier to target amyloid deposits.

Administering highly purified cannabidiol at 5 to 50 mg/kg/day reduces tonic and focal seizures by 92% to 100% in patients with PURA mutation.

Tripodal boronated complexes form reversible covalent bonds with stimuli-responsive linkers, releasing bortezomib selectively in intratumoral environments.

An ICOS agonist antibody converts T cells to an anti-inflammatory phenotype in the dorsal root ganglia.

Calcium and magnesium compounds bind oxalate in the gut to form insoluble complexes, reducing absorption and preventing kidney stone formation.

A neuroprotective mixture of phosphocreatine, magnesium gluconate, and beta-hydroxybutyrate protects brain tissue.

Cobalt contrast markers resolve negative titanium seed artifacts on MRI, enabling precise brachytherapy dosimetry.

Anti-Tau antibodies target pathological Tau conformers to resolve specificity and efficacy bottlenecks in Alzheimer's treatment.

Syringaresinol resolves blood-brain barrier permeation contradictions by selectively inhibiting excitatory synapses without disrupting inhibitory balance.

Alginate microcapsules immobilize embryonic stem cells to promote neural lineage differentiation, preventing tissue migration and adverse injury responses.

Selective fused heterocyclic S1P5 agonists isolate cognitive benefits from cardiovascular side effects caused by other receptor subtypes.

Combining selective RXR agonists with thyroid hormones treats muscular disorders while avoiding pro-inflammatory responses caused by RAR activation.

N-acetylcysteine targets oxidative stress in hemorrhagic stroke by neutralizing reactive lipid species, improving functional recovery.

Antibody-drug conjugates deliver cytotoxic agents via specific linkers, reducing toxicity to normal cells while maintaining efficacy against cancer targets.

Modified cells express non-signal-transducing chimeric polypeptides to modulate target receptor activity.

Flavone derivatives inhibit casein kinase 2 activity to reduce neuroinflammatory responses.

A liquid formulation achieves high concentration by forming a eutectic mixture that lowers the melting point, avoiding heat-induced solid-state transformation.

Protein microarrays detect maternal antibodies against fetal biomarkers like CRMP1 and LDH, resolving diagnostic accuracy versus complexity trade-offs.

CTRP3 treats rheumatoid arthritis by bypassing cytokine limitations, addressing patient variability in existing therapies.

Dinaciclib targets hPER2 phosphorylation to resolve jet lag by accelerating circadian adjustment without complex downstream mechanisms.

Anti-IL-23p19 antibodies target the unique p19 subunit to modulate immune-mediated conditions without affecting IL-12 pathways.

Selective isolation of SSEA-3 positive Muse cells from mesenchymal tissue avoids tumor risks while regenerating impaired brain tissue.

Using butyrate as a biomarker resolves the reliability gap in subjective patient reports by providing an objective measure of mood disorder improvements.

Polyclonal IgG activates FcμR receptors on Schwann cells to drive myelin gene upregulation, resolving the bottleneck of ineffective peripheral nerve repair.

Neurokinin 2 receptor agonists stimulate bladder contraction to induce voluntary urinary voiding in mammals.

SK2 channel blockers inhibit ion flow to restore neurological function, addressing inadequate treatment for fetal alcohol syndrome learning disabilities.

Optimized flavonoid ratios enable acute cognitive improvement without chronic dosing requirements.

Boswellia oil fractions mediate gastrointestinal absorption to resolve the contradiction between therapeutic efficacy and nutrient depletion.